Baxter supports the conscientious use of animals in research only when no other scientific or regulatory acceptable alternative exists to demonstrate the safety and effectiveness of the company's life-saving and life-sustaining products and therapies. The company embraces its ethical responsibility to ensure the well-being and humane care of the animals used for product development and testing. In the substantial majority of cases where Baxter uses animals, it is required by health authorities to do so.
The company is committed to using alternative protocols, methodologies and models which reduce or replace the use of animals. Baxter also works to refine current test systems to reduce animal use and improve animal welfare, while ensuring sound data are collected. For decades, the company has supported pre-clinical testing involving humane animal use that complies with all relevant local, national and transnational laws and regulations as well as additional voluntary guidelines.
Baxter's Global Animal Welfare Committee
Baxter's Global Animal Welfare Committee is composed of veterinarians and scientists with the necessary training and experience to evaluate the science, ethics and welfare of animal use. All activities involving animals must be reviewed and approved by the committee.
The committee focuses on:
- Further developing and implementing programs that will advance the 3Rs (as described below);
- Encouraging the identification of alternative test methods when opportunities exist and regulations permit;
- Setting universal standards of animal care and welfare; and
- Reviewing Baxter’s animal use, animal welfare programs, and related policies and standards.
The committee provides ongoing assessment and support of Baxter's animal testing programs to harmonize processes and tools globally. The committee's recommendations are guided by the Association for Assessment and Accreditation of Laboratory Animal Care (AALAC) International’s system of program accreditation.
Replacement, Reduction and Refinement
Baxter is committed to enhancing animal welfare through the 3Rs - replacement, reduction and refinement. The company applies a range of innovations in this area, including:
- Utilizing the company’s strength in analytical characterization of materials to assess toxicological risk in lieu of animal testing.
- Using in silico methods, when possible eliminating the need for animal testing.
- Optimizing study design, data collection and analysis methods to reduce overall animal use, in cases when Baxter is required to conduct animal testing.
- Participating in the Extractables and Leachables Safety Information Exchange and utilizing other databases of test methods to share toxicity data and minimize animal use.
- Working closely with scientists outside Baxter and industry organizations to share best practices and demonstrate continual improvement.
- Evaluating and ensuring consistently high standards for all animal care, housing methods and enrichments.
External Service Providers
Baxter only sponsors animal use activities that comply with all relevant local, national and supranational laws, regulations and guidelines (e.g. Guide for the Care and Use of Laboratory Animals1). The company conducts animal welfare assessments as part of Baxter’s overall quality and regulatory compliance program.
1Guide for the Care and Use of Laboratory Animals: Eighth Edition. Washington, D.C.: The National Academies Press, 2011.
Genetically Modified Organisms (GMO)
Cloning and the Use of Fetal and Embryonic Tissue
Baxter recognizes and respects the intrinsic distinctiveness of human embryos. Any cell lines used by Baxter or under its direction will utilize cells derived from human adults or human cell lines that were obtained as a result of a confirmed, naturally occurring event negatively affecting the continued viability of the fetus. In the event that cell lines derived from sources other than those described above are the only option for a safe and effective therapy such as the production of recombinant proteins, vaccines, and related products, Baxter's Chief Scientific Officer and Chief Executive Officer must evaluate and unanimously affirm the use of such cell line. In making the decision, the Chief Scientific Officer and Chief Executive Officer must give consideration to the following criteria:
- Viability of alternative technologies or alternative sources of cells
- Potential benefits to be realized from such use
- Probability of success for the proposed use
- Compliance with Baxter's bioethics standard